These Form 3 filings are administrative and carry no trading signal. Monitor for future Form 4 filings to track any insider transactions that may provide directional insight.
Price Chart
Executive Summary
Two insiders at Hemab Therapeutics (COAG) filed initial statements of beneficial ownership (Form 3) on April 30, 2026, disclosing warrant holdings. Director Akshay Vaishnaw holds warrants to buy 65,340 shares at exercise prices of $6.97 and $6.00, while Chief Medical Officer Catherine Madigan holds warrants to buy 310,376 shares at $7.67 and $6.00. These are routine initial ownership filings triggered by the insiders' positions and do not reflect any new transactions or material corporate events.
Key Facts
- Director Akshay Vaishnaw filed Form 3 disclosing warrants for 65,340 shares of common stock.
- Chief Medical Officer Catherine Madigan filed Form 3 disclosing warrants for 310,376 shares of common stock.
- Vaishnaw's warrants have exercise prices of $6.97 (expiring May 7, 2034) and $6.00 (expiring January 28, 2036).
- Madigan's warrants have exercise prices of $7.67 (expiring February 9, 2035) and $6.00 (expiring January 28, 2036).
- Both filings include standard powers of attorney authorizing company officers to file SEC reports on their behalf.
Financial Impact
No financial impact — routine insider ownership disclosure with no new transactions or material changes.
Risk Factors
- No material risks identified from these routine filings.
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (COAG) — Batch item 1 | 0001193125-26-198190 |
| Document: 0001193125-26-198190-index-headers.html | 0001193125-26-198189 |
| Document: 0001193125-26-198190-index.html | 0001193125-26-198190 |
| Document: 0001193125-26-198190.txt | 0001193125-26-198190 |
| 3 Filing (COAG) — Batch item 5 | 0001193125-26-198189 |
| Document: 0001193125-26-198189-index-headers.html | 0001193125-26-198190 |
| Document: 0001193125-26-198189-index.html | 0001193125-26-198190 |
| Document: 0001193125-26-198189.txt | 0001193125-26-198190 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | 8-K | $49.87 $44.50 | ▼ −10.77% | ▼ −9.71% | $30.36 (−39.12%) |
Jun 17, 2026 15w ago | Insider Buy | $29.24 $44.53 | ▲ +52.29% | ▲ +51.76% | $30.36 (+3.83%) |
May 21, 2026 19w ago | Press Release | $26.30 $31.83 | ▲ +21.03% | ▲ +20.69% | $30.36 (+15.44%) |
May 4, 2026 21w ago | 8-K | $25.00 $27.47 | ▲ +9.88% | ▲ +4.93% | $30.36 (+21.44%) |
Apr 30, 2026 22w ago | Press Release | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access